The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells
Open accessAbstract
The immunosuppressive drug cyclosporin A (CsA) has considerable nephrotoxic side effects which seem to be related to its interference with the synthesis of vasoactive prostanoids. Therefore, the molecular mechanism of the effect of CsA on the synthesis of prostaglandin E2 (PGE2) was investigated in rat renal mesangial cells (RMC). CsA effectively inhibited the PGE2 synthesis induced by inflammatory cytokines such as interleukin 1 (IL-1) or tumor necrosis alpha (TNF alpha). The induction by IL-1 and the inhibition by CsA were reflected in the enzyme activity of the cyclooxygenase. The changes in activity could be correlated with the expression of the inducible cyclooxygenase isoform (COX2), which is characterized by its 4.4 kb mRNA: the expression of this enzyme was enhanced by IL-1 and suppressed by CsA on the mRNA and protein level as determined by Northern and Western blot analyses. Suppression of COX2 mRNA was also observed when the message was induced by LPS or ionophore A23187. The expression of the basal cyclooxygenase isoform (COX1), which was constitutively expressed in proliferating mesangial cells, was not affected by IL-1 or CsA. Interferon gamma, which did not induce prostaglandin synthesis or influence COX mRNA expression, augmented the expression of MHC antigens in RMC. This induction was insensitive to CsA treatment. We could thus show that the inducible cyclooxygenase isoform in mesangial cells is a molecular target for CsA providing a possible mechanism for t…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies involving angiotensin-I-converting enzyme inhibitors have demonstrated beneficial effects on proteinuria but have not demonstrated the superiority of blockade of the renin-angiotensin system in slowing the progression to end-stage renal disease over nonblockade forms of therapy. 14-20”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [15]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O’Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 812
Prostanoid biosynthesis and mechanisms of action
Smith, W. L. (1992) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1992.263.2.f181 · Cited by 551
The long-term course of cyclosporine-associated chronic nephropathy
Myers, B. D., Sibley, R. K., Newton, L., Tomlanovich, S. J., Boshkos, C., Stinson, E. B., Luetscher, J. A., Whitney, D. J., Krasny, D., Coplon, N. S., et al. (1988) · Kidney International · doi:10.1038/ki.1988.38 · Cited by 504
Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells.
Maier, J. A. M., Hla, T., & Maciag, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38515-1 · Cited by 479
The glomerular mesangial cell: an expanding role for a specialized pericyte
Schlöndorff, D. (1987) · The FASEB Journal · doi:10.1096/fasebj.1.4.3308611 · Cited by 438
Myers, P. D. B. D. (1986) · Kidney International · doi:10.1038/ki.1986.280 · Cited by 331
English, J., Evan, A. P., Houghton, D. C., & Bennett, W. M. (1987) · Transplantation · doi:10.1097/00007890-198707000-00027 · Cited by 298
Cited by
Sorted by citations
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,527
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M. E., Dworkin, L. D., Elliott, W. J., Epstein, M., Toto, R. D., Tuttle, K. R., Douglas, J. G., Hsueh, W. A., & Sowers, J. R. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,396
Metadata
- Authors
- Martin, M., Neumann, D., Hoff, T., Resch, K., DeWitt, D. L., & Goppelt-Struebe, M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Corresponding author
- Martin, Michael
- ORCID
- Neumann, Detlef
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 1994-01
- Volume
- 45
- Issue
- 1
- Pages
- 150-158
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W1965476867
- Cited by
- 178
- References
- 42
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 4 · 2020: 1 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Kidney International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- cyclosporine, cyclooxygenase-2, interleukin-1, renal mesangial cells, prostaglandin E2 synthesis, cyclooxygenase-1, TNF-α, interferon-gamma, MHC antigen expression, cyclosporine nephrotoxicity, inflammatory cytokines
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Cells, Cultured, Glomerular Mesangium, Interleukin-1, Male, Prostaglandin-Endoperoxide Synthases, Recombinant Proteins, RNA, Messenger, Dinoprostone, Histocompatibility Antigens Class I, Cytokines, Cyclosporine, Cyclooxygenase Inhibitors, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
